Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.
Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company headquartered in Rochester, NY. Specializing in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines, and other biologic products, Vaccinex is dedicated to addressing serious diseases with unmet medical needs, including cancer, multiple sclerosis, and other autoimmune diseases.
The company is pioneering a unique approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). Vaccinex's leading drug candidate, pepinemab, is designed to block SEMA4D, a potent agent believed to prevent immune infiltration into tumors and reduce inflammation in chronic brain diseases. Currently, pepinemab is undergoing evaluation in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease. Additionally, there is ongoing exploration for potential Phase 3 development in Huntington's disease.
Vaccinex conducts research both in-house and through collaborations with prominent academic institutions and biotechnology firms. The company's proprietary drug discovery platform, ActivMAb, plays a significant role in its innovative drug development approach. The development team at Vaccinex comprises experienced industry veterans skilled in therapeutic biologics research, manufacturing, quality control, toxicology, pharmacology, regulatory affairs, and clinical affairs.
Recently, Vaccinex has achieved notable milestones, including a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards and the advancement of its clinical trials. The company continues to secure funding for its research, with significant investments from the Alzheimer’s Drug Discovery Foundation and grants from the Alzheimer’s Association.
Vaccinex remains committed to advancing its clinical programs and expanding its pipeline of innovative therapies to improve patient outcomes in challenging diseases.
Vaccinex, a biotechnology company focusing on neurodegenerative diseases, has successfully completed enrollment for its SIGNAL-AD clinical trial, aimed at evaluating pepinemab in patients with mild Alzheimer's Disease. The trial, which included 40 patients, is designed to assess safety and cognitive effects over a 52-week period. Results are expected in mid-2024. The company builds on previous positive data from its Huntington’s Disease study, reinforcing the potential of pepinemab to address neuroinflammation. Moreover, FDA feedback on a planned Phase 3 study for Huntington’s Disease is anticipated by May 16, 2023. The ongoing SIGNAL-AD trial has been supported financially by key organizations in Alzheimer’s research.
Vaccinex, Inc. (Nasdaq: VCNX), a biotechnology firm focusing on innovative treatments for neurodegenerative diseases and cancer, announced the publication of a significant research paper in Nature Communications on April 12, 2023. The study highlights their novel ActivMAb® platform, which presents a new way to study G protein-coupled receptors (GPCRs) and ion channels, deemed challenging to drug.
By utilizing a Vaccinia-based system, the research demonstrates the creation of diverse libraries of GPCR variants, enhancing expression and stability while preserving their functional characteristics. This innovation is expected to aid in drug discovery and improve the study of GPCRs, critical drug targets involved in many physiological processes. Vaccinex's lead drug candidate, pepinemab, continues clinical trials for Alzheimer's and various cancers.
Vaccinex, Inc. (Nasdaq: VCNX) announced the closing of a private placement on March 30, 2023, raising $2.04 million by selling 4,975,608 shares at $0.41 per share. Major participants included Dr. Maurice Zauderer, CEO, and Albert D. Friedberg, Chairman, who invested a combined $2.0 million. A commitment for an additional $2.96 million was made by Friedberg's entity, totaling $5.0 million in new financing. Funds will be used for the development of pepinemab, targeted at Alzheimer’s disease and cancer. Detailed terms will be outlined in a future SEC filing.
FAQ
What is the current stock price of Vaccinex (VCNX)?
What is the market cap of Vaccinex (VCNX)?
What is Vaccinex, Inc.?
Where is Vaccinex, Inc. located?
What is Vaccinex's lead drug candidate?
What is the focus of Vaccinex's research?
What clinical studies is pepinemab involved in?
What is the ActivMAb platform?
Who are Vaccinex's research partners?
What recent milestone has Vaccinex achieved?
How is Vaccinex funded?
Who leads the development team at Vaccinex?
